PMID- 37207167
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230522
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Phase I study of intra-osseous co-transplantation of a single-unit cord blood and 
      mesenchymal stromal cells with reduced intensity conditioning regimens.
PG  - 1186532
LID - 10.3389/fonc.2023.1186532 [doi]
LID - 1186532
AB  - Cord blood (CB) is a valuable graft source for patients undergoing allogeneic 
      hematopoietic cell transplant (HCT) who lack human leukocyte antigen 
      (HLA)-matched donors. However, single-unit CB-HCT is limited by the insufficient 
      cell dose and slow engraftment. To overcome these limitations, we combined a 
      single-unit CB with third-party healthy donors' bone marrow (BM) derived 
      mesenchymal stromal cells (MSCs) to improve engraftment and injected 
      intra-osseously (IO) to enhance homing. In this phase I clinical trial, six 
      patients with high-risk hematologic malignancies were enrolled and received 
      allogeneic HCT using reduced intensity conditioning regimens. The primary 
      objective was to determine the engraftment rate at day 42. The median age of 
      enrolled patients was 68 years, and only one patient was in complete remission at 
      the time of HCT. The median CB total nucleated cell dose was 3.2x10(7)/kg. No 
      serious adverse events were reported. Two patients had early deaths due to 
      persistent disease and multi-drug resistant bacterial infection, respectively. Of 
      the remaining four evaluable patients, all had successful neutrophil engraftment 
      in a median of 17.5 days. No grade 3 or higher acute graft-versus-host disease 
      (GvHD) was observed, and only one patient developed moderate-extensive chronic 
      GvHD. In conclusion, IO co-transplantation of a single-unit CB and MSCs was 
      feasible and resulted in a reasonable engraftment rate in these very high-risk 
      patients.
CI  - Copyright (c) 2023 Wang, Sanati, Firoozmand, Fu, Kolk, Reese-Koc, de Lima, Boughan, 
      Cooper, Caimi, Gallogly, Otegbeye, Tomlinson and Metheny.
FAU - Wang, Jiasheng
AU  - Wang J
AD  - Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, 
      Cleveland, OH, United States.
FAU - Sanati, Farhad
AU  - Sanati F
AD  - Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, 
      Cleveland, OH, United States.
FAU - Firoozmand, Amin
AU  - Firoozmand A
AD  - Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, 
      Cleveland, OH, United States.
FAU - Fu, Pingfu
AU  - Fu P
AD  - Case Western Reserve University, Cleveland, OH, United States.
FAU - Kolk, Merle
AU  - Kolk M
AD  - Adult Hematologic Malignancies & Stem Cell Transplantation Service, University 
      Hospitals Seidman Cancer Center, Cleveland, OH, United States.
FAU - Reese-Koc, Jane
AU  - Reese-Koc J
AD  - Case Western Reserve University, Cleveland, OH, United States.
FAU - de Lima, Marcos
AU  - de Lima M
AD  - Division of Hematology, Ohio State University, Columbus, OH, United States.
FAU - Boughan, Kirsten
AU  - Boughan K
AD  - Department of Hematology/Oncology, Louis Stokes Veterans Affairs Medical Center, 
      Cleveland, OH, United States.
FAU - Cooper, Brenda
AU  - Cooper B
AD  - Adult Hematologic Malignancies & Stem Cell Transplantation Service, University 
      Hospitals Seidman Cancer Center, Cleveland, OH, United States.
FAU - Caimi, Paolo
AU  - Caimi P
AD  - Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH, United 
      States.
FAU - Gallogly, Molly
AU  - Gallogly M
AD  - Adult Hematologic Malignancies & Stem Cell Transplantation Service, University 
      Hospitals Seidman Cancer Center, Cleveland, OH, United States.
FAU - Otegbeye, Folashade
AU  - Otegbeye F
AD  - Clinical Research Division, Fred Hutchison Cancer Center, Seattle, WA, United 
      States.
FAU - Tomlinson, Benjamin
AU  - Tomlinson B
AD  - Adult Hematologic Malignancies & Stem Cell Transplantation Service, University 
      Hospitals Seidman Cancer Center, Cleveland, OH, United States.
FAU - Metheny, Leland
AU  - Metheny L
AD  - Adult Hematologic Malignancies & Stem Cell Transplantation Service, University 
      Hospitals Seidman Cancer Center, Cleveland, OH, United States.
LA  - eng
PT  - Journal Article
DEP - 20230503
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10191226
OTO - NOTNLM
OT  - allogeneic hematopoietic cell transplantation
OT  - cord blood
OT  - intra-osseous
OT  - mesenchymal stromal cells
OT  - reduced intensity conditioning
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/19 19:14
MHDA- 2023/05/19 19:15
PMCR- 2023/01/01
CRDT- 2023/05/19 15:52
PHST- 2023/03/14 00:00 [received]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/05/19 19:15 [medline]
PHST- 2023/05/19 19:14 [pubmed]
PHST- 2023/05/19 15:52 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1186532 [doi]
PST - epublish
SO  - Front Oncol. 2023 May 3;13:1186532. doi: 10.3389/fonc.2023.1186532. eCollection 
      2023.